<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01940081</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiomyopathy study</org_study_id>
    <nct_id>NCT01940081</nct_id>
  </id_info>
  <brief_title>The Leiden Nonischemic Cardiomyopathy Study</brief_title>
  <official_title>The Leiden Nonischemic Cardiomyopathy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Sudden cardiac death, mainly caused by ventricular arrhythmias (VA), is a major
      cause of morbidity and mortality in non-ischemic cardiomyopathy (NICM). Therapies that
      effectively prevent VA are lacking. Improved understanding of the substrate and mechanisms
      of VA in NICM may allow more effective, individualized and substrate-based therapies to be
      developed. In addition, risk stratification in NICM needs to be improved so that therapies
      can be allocated more efficiently.

      Objectives: 1) To improve our understanding of the underlying pro-arrhythmic substrate and
      electrophysiologic mechanisms of VA in NICM, and to develop individualized treatment for VA
      based on the identified substrate. 2) To improve risk stratification for VA and sudden
      cardiac death in NICM based on substrate characteristics. 3) to evaluate disease progression
      in NICM.

      Hypothesis: Improved understanding of the substrate and mechanisms of VA in NICM may allow
      more effective, individualized and substrate-based therapies to be developed.

      Study design: A prospective cohort study.

      Study population: The study population will consist of three groups (A, B and C): NICM
      patients with documented VA, suspected VA or intermediate to high risk for VA (according to
      established criteria) who are not referred for cardiac surgery (group A), NICM patients with
      documented VA, suspected VA or a high risk for VA who are referred for cardiac surgery
      (group B) and a control group consisting of patients without NICM who are referred for
      cardiac surgery (group C).

      Evaluation: All patients will be evaluated according to current standards for patients with
      NICM. Evaluation will include 24h-Holter, echocardiography, coronary angiogram and
      contrast-enhanced MRI (CE-MRI). If CE-MRI is performed in another hospital, additional
      recordings will be performed in our hospital. Additionally, blood samples (arterial, cardiac
      venous and peripheral venous) for collagen turnover markers will be taken from all patients.
      123-iodine metaiodobenzylguanidine (123-I MIBG) imaging, electrophysiologic study and
      endomyocardial biopsy will be performed in group A and B. Intra-operative biopsy will be
      performed in group B and C.

      Intervention: In group B, intra-operative mapping and cryo-ablation and postoperative
      electrophysiologic study will be performed in patients with subepicardial late enhancement
      on MRI or induced VA suspected for an subepicardial origin.

      Main study parameters/endpoints: The main study parameters are extent, location and pattern
      of fibrosis on imaging and in biopsy specimens. The main study endpoints are inducibility of
      VA, type of induced VA, spontaneous VA and type of spontaneous VA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Inducibility of ventricular arrhythmias</measure>
    <time_frame>Baseline electrophysiological study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of induced ventricular arrhythmias</measure>
    <time_frame>Baseline electrophysiological study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous ventricular arrhythmias</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of spontaneous ventricular arrhythmias</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions for heart failure</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function/dimensions/compact fibrosis deterioration as assessed by 123-I MIBG imaging and/or CE-MRI</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <description>Patients with nonischemic cardiomyopathy with:
documented ventricular arrhythmia or
suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
high risk for ventricular arrhythmia (LVEF ≤ 35%) or
intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)
who are not admitted for cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <description>Patients with nonischemic cardiomyopathy with:
documented ventricular arrhythmia or
suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
high risk for ventricular arrhythmia (LVEF ≤ 35%)
who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Controls</arm_group_label>
    <description>Patients without nonischemic cardiomyopathy (controls) who are admitted for:
Coronary artery bypass graft surgery and who do not have prior myocardial infarction
Aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transthoracic echocardiography</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise test</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>24-hour Holter electrocardiogram</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast-enhanced magnetic resonance imaging</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>123-iodine metaiodobenzylguanidine imaging</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive electrophysiological study</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial biopsy</intervention_name>
    <arm_group_label>Group A: Nonischemic cardiomyopathy - not admitted for surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative biopsy</intervention_name>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
    <arm_group_label>Group C: Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative mapping and/or ablation</intervention_name>
    <arm_group_label>Group B: Nonischemic cardiomyopathy  -admitted for surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Per patient:

      Blood samples (40 mL) Ventricular biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with nonischemic cardiomyopathy and controls who are admitted to the hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria, group A:

          -  Nonischemic cardiomyopathy

          -  Documented ventricular arrhythmia, suspected ventricular arrhythmia (e.g. because of
             out-of-hospital cardiac arrest, palpitations or syncope) or high risk for ventricular
             arrhythmias (LVEF ≤ 35%) or intermediate risk for ventricular arrhythmias (LVEF ≤ 50%
             and late enhancement on contrast-enhanced MRI)

          -  Admission not for cardiac surgery

        Inclusion criteria, group B:

          -  Nonischemic cardiomyopathy

          -  Documented ventricular arrhythmia or suspected ventricular arrhythmia (e.g. because
             of out-of-hospital cardiac arrest, palpitations or syncope) or high risk for
             ventricular arrhythmia (LVEF ≤ 35%)

          -  Admission for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)

        Inclusion criteria, group C:

        - Patients undergoing aortic valve replacement or coronary artery bypass graft surgery

        Exclusion criteria, all groups:

          -  Age &lt; 18 years or &gt; 80 years

          -  Inadequate patient competence

          -  Pregnancy

          -  Inability to comply with the protocol due to haemodynamic instability

        Exclusion Criteria, groups A and B:

        - Other cardiomyopathy (e.g., prior myocardial infarction, infiltrative cardiac disease
        such as sarcoidosis, amyloidosis or Chagas cardiomyopathy, arrhythmogenic right
        ventricular cardiomyopathy/dysplasia, hypertrophic cardiomyopathy, non-compaction
        cardiomyopathy and congenital heart disease)

        Exclusion criteria, group C:

          -  Nonischemic cardiomyopathy

          -  Prior myocardial infarction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Cardiology, Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Zeppenfeld, MD, PhD</last_name>
      <phone>0031715266933</phone>
      <email>k.zeppenfeld@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Katja Zeppenfeld, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastiaan Piers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 7, 2013</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Katja Zeppenfeld</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Cardiomyopathy, Dilated</keyword>
  <keyword>Tachycardia, Ventricular</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>Arrhythmias, Cardiac/etiology</keyword>
  <keyword>Arrhythmias, Cardiac/physiopathology</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>3-Iodobenzylguanidine/diagnostic use</keyword>
  <keyword>Sympathetic Nervous System/radionuclide imaging</keyword>
  <keyword>Electrophysiologic Techniques, Cardiac</keyword>
  <keyword>Biopsy</keyword>
  <keyword>Genetic Testing</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Electrocardiography, Ambulatory</keyword>
  <keyword>Exercise Test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
